Source comparison
BPC-157 Joint Support Results Timeline Comparison
Week 1 (Days 1–7) VEGF upregulation, fibroblast migration, cytokine modulation No noticeable improvement. Pain/ROM unchanged Inflammatory markers reduced 10–15% (requires lab testing) Initiation phase. Absence of improvement is expected and normal Week 2–3 (Da
This comparison does not assign a generated winner or score.
- Week 1 (Days 1–7)
- VEGF upregulation, fibroblast migration, cytokine modulation
- No noticeable improvement. Pain/ROM unchanged
- Inflammatory markers reduced 10–15% (requires lab testing)
- Initiation phase. Absence of improvement is expected and normal
- Week 2–3 (Days 8–21)
- Angiogenesis, type III collagen deposition, early capillary formation
- Mild pain reduction with specific movements, slight ROM improvement
- Pain-pressure threshold improves 15–25%, no load capacity change yet
- First functional signals appear. Still too early to assess protocol efficacy
- Week 4–6 (Days 22–42)
- Type I collagen remodeling, tendon stiffness normalization, mechanical strength recovery
- Clear functional improvement. Reduced pain during activity, improved load tolerance
- Tensile strength reaches 60–70% of pre-injury baseline, ROM approaching normal
- Primary efficacy window. Most protocols show clear divergence from placebo here
- Week 8+ (Days 56+)
- Continued scar tissue remodeling, adhesion reduction, fiber alignment optimization
- Near-complete functional recovery in acute injuries; chronic cases show progressive improvement
- Mechanical properties approach pre-injury levels; imaging shows structural normalization
- Consolidation phase. Extended protocols in chronic cases yield superior long-term outcomes